Tesla shares dip after being overtaken by BYD as world’s largest EV maker

10

Elon Musk’s Tesla shares dipped as it was dethroned by the Chinese automaker BYD in electric vehicle (EV) sales in the fourth quarter of 2023.

While Tesla remains the global EV leader on an annual basis, BYD is emerging as a strong competitor in the race to become the world’s largest seller of electric vehicles.

Beyond surpassing Tesla in all-electric sales, BYD achieved sales of over 400,000 plug-in hybrid electric vehicles in the fourth quarter, contributing to a total of more than three million passenger vehicles sold last year.

Now, “the next twelve months look like they could be challenging for the company that had been streets ahead in the EV race up until now,” said Danni Hewson, head of financial analysis at AJ Bell.

Tesla’s shares were down by almost 1% in the US premarket, while BYD’s were up by almost 0.50% at the time of writing on Wednesday.

BYD’s achievement comes on the back of six consecutive months of setting new records in monthly sales.

The positive results and the rise in the brand’s global market share have propelled BYD to become the world’s top seller of plug-in cars and the fifth best-selling car brand globally.

The Shenzhen-based automaker operates in 59 countries, including major markets such as China, the European Union, the United Kingdom, Japan, and Korea.

However, it does not currently sell in the US due to the high import tariffs.

Furthermore, in September 2023, the European Commission initiated a probe to consider the imposition of punitive tariffs with the aim of safeguarding European Union producers from the influx of inexpensive Chinese EV imports. 

“While price is something that is being probed by EU regulators and could create a bit of a speed bump down the road, momentum is currently on BYD’s side. Though Tesla managed to hang onto the EV crown in 2023, it’s coming under increasing pressure from legacy carmakers and Chinese models alike,” Hewson added.

10 investing lessons from the late investment legend Charlie Munger

Investing is a complex and ever-evolving field that demands a blend of astute decision-making, comprehensive analysis, and a deep understanding of human behaviour.

The late Charlie Munger, Vice Chairman of Berkshire Hathaway and renowned investing guru, left behind a legacy of wisdom that transcends the mere financial aspects of the market. In this article, we will explore 10 investing phrases coined by Charlie Munger and the valuable lessons they impart to investors.

  1. “Invert, always invert”:

Munger’s emphasis on inversion encourages investors to think backwards. Instead of focusing solely on positive outcomes, consider potential pitfalls. By adopting this approach, investors can make more well-informed decisions and better navigate the complexities of the market.

Lesson: Sound decision-making involves a comprehensive evaluation of both positive and negative aspects, offering a more holistic perspective.

  1. “It’s not supposed to be easy. Anyone who finds it easy is stupid”:

Munger debunked the myth of easy money in investing. He stressed the importance of hard work, continual learning, and rational decision-making in the face of the market’s inherent complexities.

Lesson: Success in investing demands diligence, continuous learning, and a commitment to making well-informed decisions rather than seeking shortcuts.

  1. “Avoiding stupidity is easier than seeking brilliance”:

Munger advocates for steering clear of common pitfalls and mistakes in investing. By sidestepping foolish decisions, investors can often achieve better results than by constantly chasing after brilliant strategies.

Lesson: Minimising errors and avoiding common pitfalls can lead to more consistent and successful investment outcomes.

  1. “Circle of competence”:

Munger encourages investors to operate within their circle of competence, investing only in businesses and industries they thoroughly understand. Straying beyond this circle increases the likelihood of making uninformed decisions.

Lesson: Identify your strengths and invest in companies that fall within your circle of competence to enhance the chances of making sound investment choices.

  1. “Spend each day trying to be a little wiser than you were when you woke up”:

Munger believed in the importance of continuous learning. He urged investors to strive for incremental improvement each day, accumulating knowledge and wisdom over time.

Lesson: Consistent self-improvement and learning are vital for long-term success in investing. Stay curious and seek opportunities for growth.

  1. “The best way to get what you want is to deserve what you want”:

Munger stressed the significance of merit and hard work. Instead of fixating solely on desires, investors should focus on developing the skills and knowledge necessary to achieve their goals.

Lesson: Success in investing comes from deserving success through disciplined research, thoughtful decision-making, and a commitment to personal growth.

  1. “It’s waiting that helps you as an investor, and a lot of people just can’t stand to wait”:

Patience is a virtue in investing, according to Munger. Successful investors understand the power of waiting for the right opportunities and avoiding impulsive decisions driven by short-term market fluctuations.

Lesson: Develop the patience to wait for high-quality investment opportunities, and resist the urge to make hasty decisions based on short-term market movements.

  1. “A great business at a fair price is superior to a fair business at a great price”:

Munger emphasized the importance of investing in high-quality businesses, even if they come at a higher price. The long-term potential and stability of a great business often outweigh the immediate gains from a cheaper, less promising investment.

Lesson: Prioritise the quality of businesses in your portfolio over their current valuation. A great business can generate sustainable returns over time.

  1. “It is remarkable how much long-term advantage people like us have gotten by trying to be consistently not stupid, instead of trying to be very intelligent”:

Munger stressed the value of avoiding mistakes rather than focusing solely on being exceptionally intelligent. By minimising errors, investors can create a significant long-term advantage.

Lesson: Consistent, rational decision-making and avoiding common pitfalls can lead to better investment results than attempting to be overly clever.

  1. “The big money is not in the buying or selling, but in the waiting”:

Munger underscores the importance of patience and a long-term perspective. Successful investing often involves holding onto quality investments through market ups and downs rather than constantly buying and selling.

Lesson: The real profits come from holding onto solid investments over an extended period. Resist the temptation to engage in frequent trading and focus on the long-term potential of your portfolio.

ANGLE shares continue march higher after signing cancer trial agreement

ANGLE, the London-listed liquid biopsy company specialising in innovative circulating tumor cell (CTC) diagnostic solutions, continued to surge higher on Wednesday after inking a significant deal with global pharmaceutical giant Eisai Inc yesterday.

ANGLE shares were 12% higher at the time of writing on Wednesday.

In a groundbreaking pilot study valued at $250,000, ANGLE is set to provide CTC analysis using its cutting-edge Portrait HER2 assay. The focus of this study is to evaluate the HER2 (human epidermal growth factor receptor 2) status of breast cancer patients participating in a Phase II trial of the HER2 targeting antibody-drug conjugate (ADC) BB-1701.

The success of this pilot study holds the potential for numerous large-scale follow-up investigations, marking a potentially pivotal moment in cancer research and drug development.

ANGLE’s Portrait HER2 assay stands out for its ability to quantitatively assess both HER2 protein expression (via IF) and HER2/neu gene amplification (via FISH).

This dual-pronged approach is crucial in identifying breast cancer patients who could benefit from anti-HER2 ADC treatment. Notably, HER2-low breast cancer, comprising 55% of all breast cancer cases, represents a significant portion of the market.

Analysts predict that the global HER2+ breast cancer ADC market is poised to reach a staggering US $3.3 billion per annum by 2030. With the market expanding into HER2-low patients, ANGLE’s strategic move to develop a quantitative HER2 assay becomes even more pivotal. This assay allows for the precise stratification of patient populations throughout the treatment pathway, considering that HER2 status can dynamically change over time.

Oil rally continues as an Iranian warship enters the Red Sea

Oil prices jumped again by more than 2% on Tuesday after an Iranian warship entering the Red Sea after U.S. helicopters sank three Houthi boats on Sunday.

Iran first announced the deployment of the Alborz destroyer through the strategic Bab al-Mandeb Strait on Monday, as reported by the Iranian state media.

The details of the warship’s mission were not disclosed, but the statement mentioned that such maritime operations are normal and are carried out from time to time in the Red Sea in order to secure shipping routes.

However, the move comes after the U.S. Navy destroyed three out of four Houthi rebel boats on Sunday, killing ten organisation members as a result.

The Navy was responding to a distress call from the Singapore-flagged container vessel Maersk Hangzhou, which was being shot at by Houthi rebels, as stated by the U.S. Central Command.

A Houthi spokesperson then commented on Sunday on the rebel-owned news channel that the Houthi’s open fire on the Maersk Hangzhou vessel was in line with the group’s “official duties to secure maritime routes.”

In light of the Sunday attack, the Danish shipping company Maersk stated that it will announce later on Tuesday whether or not it will redirect its shipping route to around Africa.

As the tension continued to heighten on the news of an Iranian warship now patrolling the Red Sea, Brent Crude was up by 2.40%, while WTI Crude was up by 2.44% at the time of writing on Tuesday.

Since the first Houthi Red Sea-based attack back in December, more and more major oil companies have been diverting their shipping routes from the Red Sea to a safer passage around Africa.

Ship tracking data, released at the end of December, shows that at least four Europe-bound ships took a longer route around Africa in order to avoid crossing the Red Sea.

The route to Europe from India or the Middle East around Africa is not only approximately three weeks longer but is also much more expensive, with ocean freight rates surging to as much as $10,000 (£7,844) per container.

Therefore, a significant number of vessels continue to favour the Red Sea, with some taking an even riskier and shorter route through the Suez Canal.

Oil volatility

Despite the current rally, which was highlighted by benchmark crude Brent jumping up by more than 2.50% at the time of writing on Tuesday, oil has had a difficult December.

In the middle of the last month, the front-month WTI briefly fell below $68, hitting its lowest point since June 2023.

“It found support there and went on to break above $76 per barrel two weeks later. Prices have stabilised since, and where we go from here over the next week or so is likely to be significant in setting the path for oil in the first quarter of 2024,” said David Morrison, senior market analyst at Trade Nation.

However, in the final trading sessions before Christmas, oil prices experienced a significant retreat, causing many traders to speculate that the likelihood of a more substantial rally had diminished.

“If the current rally fades quickly, then a retest of support down to $67.50 is possible. If prices gain some upside momentum, then a rally could have legs given how far crude oil has fallen since the end of September,” said Morrison.

“Fundamentally, while supply continues to outstrip demand, the escalating hostilities in the Red Sea are raising concerns and providing support,” he added.

Looking into the future, a survey conducted by Reuters among economists and analysts forecasts that in 2024, the average for Brent crude will be around $82.56 per barrel.

This projection is slightly above the 2023 average of $82.17.

Cash burners can fire outstanding returns

By James Henderson

While balance sheet discipline is often a welcome feature of a potential investment, occasionally it pays to consider businesses that are spending cash on themselves, as we have done for Lowland Investment Company.

Listen to any fund manager presentation and the core script will almost invariably include lines like this: “We buy strong, growing companies that are generating lots of cash and have strong balance sheets and barriers to competition… Blah, blah…”

Well, perhaps not “Blah, blah…” ­– but you get the gist. It would be nice to hear a manager say that sometimes they include in their portfolio companies burning cash so fast that without an urgent injection of capital they face ruin.

You might ask why on earth anyone would want such a company, but many of the best investments I have ever made have fallen into this category. One of our best performers this year has been Rolls-Royce, which is up 140% so far.

This is a company that in January was described by its new boss as a “burning platform”. Tufan Erginbilgic pointed to the disappointing returns made on invested capital and set about changing things.

He has sold off non-core businesses – one of the largest being the €1.8bn disposal of Spanish joint venture ITP Aero. He has focused spending on priority areas and renegotiated maintenance contracts.

Post-Covid recovery in air transport has helped. The combination means that in just the first six months of the year operating margins soared from 3.4% to 12.4% and the company generated twice as much profit as analysts were expecting – £673m.

Those earlier analyst forecasts have shown how a gloomy mindset can set in around a company. Rolls-Royce was certainly not one for investors who only like companies with attractive cash flows. They have missed out.

Unearthing these opportunities takes research. Often you are looking for yesterday’s leaders in recovery, like Rolls-Royce. But more usually you find them in smaller companies. When investing in these businesses you must always be aware that at some point you may be touched for more cash – or see your shares diluted. It is called a “rights issue”.

It is easy to forget that the purpose of the stock exchange is to help companies raise capital. In return they offer a stake in the business and a share of all future profits for as long as the company operates and those shares are in operation.

Companies can seek to raise cash for all sorts of reasons. In the AIM market it would usually be to build new plant, expand production or take a new product from prototype to production. Examples in our portfolio include alternative energy companies such as AFC, ITM and Ceres. These are still fairly early-stage businesses but could have enormous potential as we move to a low-carbon world.

Sometimes companies can experience a cash squeeze because of events, like Covid. For investors who support any fund-raising endeavours the hope may be that if the business can get through to the other side of the crisis it will find competition weakened and gain significant market share.

One of the most memorable examples of a company raising capital because of a crisis was in 2001. Following the terrorist attack on the Twin Towers in New York, insurer Hiscox came to the market twice – in 2001 and 2002 – seeking around £164m. We backed it. With that money it was able to write new business at an attractive rates, because many of its competitors were out of the market in light of their own cash struggles. It helped enable Hiscox, then a relatively small business, to step into the big leagues. The rights issue shares were £1.20 and £1.65. Today Hiscox shares trade at more than £10.

There is heightened risk in cash burning investments, but risks can be mitigated. We want to understand clearly what is behind the cash burn and how quickly investment might be expected to pay off. Is it a Covid-style crisis and a story of the fittest survivor thriving when normal service resumes?

A crucial question we ask ourselves is how much we trust management. Often new management will launch a rights issue as part of a big reorganisation plan. Does that plan excite us? Can we see the potential or is it pouring good money after bad?

It might be that the plan is not articulated well and is not convincing. It might be that we do not have confidence in management’s ability to execute it. In such cases we may not just decline to pay up – we may sell our shares altogether. Sometimes it is better to take your losses and move on, putting your money to work in more promising areas.

Of course, we have had failures, but when you get the decision right the rewards from a cash burner can far outpace those offered by the majority of healthy cash generators that can form the core of portfolios.

Find out more here


Important information

References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

Not for onward distribution. Before investing in an investment trust referred to in this document, you should satisfy yourself as to its suitability and the risks involved, you may wish to consult a financial adviser. This is a marketing communication. Please refer to the AIFMD Disclosure document and Annual Report of the AIF before making any final investment decisions. Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor’s particular circumstances and may change if those circumstances or the law change. Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Issued in the UK by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK  Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), (each registered in England and  Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial  Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier).

Janus Henderson and Knowledge Shared are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc

These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.

Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

The information in this article does not qualify as an investment recommendation.

Marketing Communication.

Glossary

Balance sheet

A financial statement that summarises a company’s assets, liabilities and shareholders’ equity at a particular point in time. Each segment gives investors an idea as to what the company owns and owes, as well as the amount invested by shareholders. It is called a balance sheet because of the accounting equation: assets = liabilities + shareholders’ equity.

Barriers to entry

Factors that can prevent or hinder new competitors from entering into an industry or business area, such as high start-up costs, patents, technical knowledge, brand loyalty etc.

Capital

When referring to a portfolio, the capital reflects the net asset value of a fund. More broadly, it can be used to refer to the financial value of an amount invested in a company or an investment portfolio.

Free cash flow (FCF)

Cash that a company generates after allowing for day-to-day running expenses and capital expenditure. It can then use the cash to make purchases, pay dividends or reduce debt.

AIM movers: LungLife AI validates lung cancer test and Plexus licence deal

2

LungLife AI Inc (LON: LLAI) has successfully validated its LungLB early lung cancer detection test. The positive predictive value was 81% in distinguishing cancer nodules smaller than 15mm. The current standard is 60%. There will be an early access programme offered in the first quarter of 2024. The test will be optimised for additional uses. The share price initially rose above 70p and it is currently 30.4% ahead at 60p.

Sareum (LON: SAR) says that its co-development partner CRT Pioneer Fund has entered into a development and commercialisation licence for SRA737 with a US biopharmaceutical company. SRA737 is an oral, selective checkpoint kinase 1 inhibitor that targets cancer cell replication. There will be an upfront payment of $500,000 to CRT Pioneer Fund with potential for an additional fee of up to $1m in cash and 500,000 shares. There could be payments of up to $289m if a successful drug is developed, plus high single-digit royalties. The share price jumped 21.9% to 72.5p.

Extractions Premium & Mining has converted £250,000 of loan notes in oil and gas explorer Corcel (LON: CRCL) at 0.8p/share. That leaves a balance of £750,000. Corcel executive chairman Antoine Karam owns 45% of Extractions Premium & Mining. The share price improved 18.3% to 0.81p.

Drug development services provider Proteome Sciences (LON: PRM) has completed the installation of equipment at its new laboratory in San Diego, which will service growing demand in the US.

Oriole Resources (LON: ORR) expects execution of the earn-in agreements with BCM for the Mbe and Bibemi gold exploration projects in Cameroon to happen this month. That will trigger payments of $1m and $450,000 respectively. BCM will then spend $4m on exploration to earn 50% of each of the projects. Managem has decided not to invest any more cash in the Senala project in Senegal, so Oriole will retain ownership of Senala. After an initial fall, the share price moved up 3.09% to 0.17525p.

FALLERS

Plexus Holdings (LON: POS) has extended an IP licence agreement with SLB, which replaces a previous surface production wellhead licence agreement with a subsidiary of SLB. For $5.2m in cash, SLB gets a licence in perpetuity to use POS-GRIP technology, including HG sealing technology. This licence covers areas of the market that are not a focus of Plexus. The 2023-24 revenues forecast has been upgraded to £14m and pre-tax profit raised by 467% to £1.7m. Net cash should be £3.8m at the end of June 2024. However, this is a one-off, so Plexus could fall back into loss next year. Plexus was the best AIM performer in 2023. The share price slipped 17.9% to 17.25p.

A general meeting has agreed to change the name of Barkby Group (LON: BARK) to Roadside Real Estate, which will be LON:ROAD. Barkby is refinancing its debt and a change to the articles of association will enable more to be borrowed. The share price declined 5.51% to 6p.

Real-time oil condition analysis company Tan Delta Systems (LON: TAND) says that progress has been slower than hoped since floating in August. Full year revenues will decline from £1.6m to £1.44m, which is lower than expected. Customer trials have been delayed, but there has been greater interest in the technology. The loss will be in line with expectations at £400,000. Cash was £4.5m at the end of the year. The placing price was 26p. The share price fell 4.35% to 22p.

Tekcapital’s Belluscura set for a landmark year

Tekcapital portfolio company Belluscura is positioned for a landmark 2024.

The stars are aligning for the developer and manufacturer of portable oxygen units after securing interest and orders totalling up to a potential $85m last year.

In addition, the company is on the verge of completing an innovative funding package designed to meet the demands of burgeoning orders in Asia.

The company has received approval in Singapore, Hong Kong, and, most recently, China. China represents a market of up to 100 million suffering from COPD.

“We are delighted to have received approval in China which has taken over approximately 10 months. This enables us to launch sales into China with immediate effect,” said Bob Rauker, Chief Executive Officer of Belluscura when the company released a trading update in December.

“With our arrangement with InnoMax in place, we are confident that we can now deliver on the significant potential for our products in this large and growing market.

“The approval in China, Singapore and Hong Kong are the first steps in leveraging the InnoMax agreement to expand in the ASEAN region and to distribute our portable oxygen concentrators in new markets, enhancing the lives of those with COPD and building market share in the process.

“Building any start up business is never easy, particularly within the MedTech world and in the current economic environment. After two years of testing, developing and refining our products, the Board is very confident that Belluscura is now well placed to take advantage of the significant opportunities it has in 2024 and beyond.”

This year is likely to be the year Belluscura transitions from the ‘start up’ phase Rauker mentioned, to a scale up multinational organisation generating significant revenues.

Belluscura’s lowly £35m market capitalisation may start to look excellent value as the company builds momentum.

The company was founded by Tekcaptial (LON:TEK), who retain a circa 10% stake. Tekcapital recently said they were continuing to progress with another AIM IPO from their stable of technology companies, MicroSalt.

MicroSalt has won substantial contracts with the world’s largest snack food companies and like Belluscura, is set for a year of multi-million pound revenue generation.

Why companies left AIM in November 2023

There were nine companies leaving AIM in November. Four were taken over, three got into financial difficulties, one decided to cancel its quotation and one decided to go into liquidation and distribute investments and cash to shareholders. There were no new admissions during the month.

3 November

Global Invacom

Satellite communications equipment provider Global Invacom gained shareholder approval for the cancellation of the AIM quotation. The shares are still traded on the Main board of the Singapore Exchange Securities Trading Ltd. A lack of liquidity and access to capital, plus dup...

Growth: Keeping track of vessels on the seas

This company already has most of its forecast revenues for 2024 in the bag with annualised recurring revenues nearly as high as the forecast. It remains loss making but has a substantial cash buffer that is more than enough to ensure that the business reaches profitability before it runs out. That could happen by the end of 2025.

The company has confirmed that the 2023 results will be comfortably in line with forecasts. Demand for the company’s services is growing on the back of increasing sanctions activity in global trade.

Maritime AI technology services provider Windward (LON: WNWD) ...

AIM new admission: Gas prospects in the UK Irish Sea Basin

Standard list shell Dial Square Investments moved to AIM at the same time as the reverse takeover of EnergyPathways and it subsequently changed its name to the latter. The original intention was to seek a sports management business, but instead it acquired a developer of UK gas assets.

The focus is near-term, low emission energy and it has an interest in a block in the UK Irish Sea Basin. This could help to provide energy security for the UK. The cash raised will fund initial field development before the drilling of wells.

The shares had been suspended at 3.25p and they ended the first ...